# CD318-targeted CAR-T Cell Therapy in Patients With Pancreatic Cancer (ResCPa)

Source: https://onco.cc/trials/nct07153289/  
OnCo record `nct07153289` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial in pancreatic cancer, run by University Hospital Tuebingen, not yet recruiting.

## Summary

CD318-targeted CAR-T Cell Therapy in Patients With Pancreatic Cancer (ResCPa) is a phase 1/2, interventional study registered as NCT07153289 by University Hospital Tuebingen, with a registry enrolment figure of 38 participants, started 2026-07 and due to reach its primary completion in 2028-12. Interventions recorded: CD318-CAR-T cells. Conditions listed: Carcinoma, Pancreatic Ductal; Pancreatic Neoplasms. Primary outcome: Incidence and severity of dose-limiting toxicities (DLTs) and adverse events (AEs) after CD318-CAR-T cell infusion.. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Also known as: ResCPa
- Tags: ctgov-ingest; pancreatic-deep-dive
- Registry id: NCT07153289
- Phase: 1/2
- Setting: Response Features, Efficacy and Safety of CD318-targeted CAR-T Cell Therapy Against Pancreatic Cancer - ResCPa Study
- Sponsor: University Hospital Tuebingen
- Enrolled: 38

## Sources

- ClinicalTrials.gov NCT07153289: https://clinicaltrials.gov/study/NCT07153289

## Connected records

- cancers: [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- technologies: [CAR-T cell therapy](https://onco.cc/technologies/car-t/)
- terms: [Pancreatic cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/pancreatic-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07153289.json